Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS)

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My last two ratings on Apellis Pharmaceuticals, Inc. ( APLS ), the Waltham, Massachusetts-based pharma company and complement system specialist, have been Holds, the first beingEdmund Ingham is a biotech consultant ...